Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 0.53 |
| ▸ | ADRB1 known ✓ | P08588 | 15/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3042203 | 1.00 | ADRB2 (0.53) | ADRB2ADRB1 | |
| SCHEMBL1039882 | 0.95 | ADRB2 (0.56) | ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL3050623 | 0.95 | ADRB2 (0.57) | ADRB2ADRB1 | |
| Bromide SCHEMBL3059151 | 0.95 | ADRB2 (0.55) | ADRB2ADRB1 | |
| Malic Acid SCHEMBL3048507 | 0.92 | ADRB2 (0.52) | ADRB2ADRB1 | |
| Fumaric Acid SCHEMBL3051345 | 0.92 | ADRB2 (0.56) | ADRB2ADRB1 | |
| Maleic Acid SCHEMBL3051341 | 0.92 | ADRB2 (0.56) | ADRB2ADRB1 | |
| Maleic Acid SCHEMBL3058731 | 0.90 | ADRB2 (0.58) | ADRB2ADRB1 | |
| Fumaric Acid SCHEMBL3058735 | 0.90 | ADRB2 (0.58) | ADRB2ADRB1 | |
| Maleic Acid SCHEMBL3055528 | 0.89 | ADRB2 (0.59) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | ADRB1, ADRA1A, ADRB2 | ADRB2 3/4885ADRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.